Stock of the Day

July 16, 2024

Alnylam Pharmaceuticals (ALNY)

$250.59
-$0.41 (-0.2%)
Market Cap: $32.49B

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

  • Alnylam Pharmaceuticals, Inc. has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards the stock's future performance.
  • The recent price target set by Scotiabank at $300.00 suggests a potential upside of 16.98% from the current stock price of $256.45, which could attract investors looking for growth opportunities.
  • Several analysts have recently upgraded their ratings and price targets, with Barclays increasing their target to $329.00, reflecting confidence in the company's future prospects.
  • Alnylam Pharmaceuticals, Inc. has a solid market capitalization of $33.08 billion, which indicates a stable financial foundation and the ability to invest in research and development.
  • The company focuses on innovative therapeutics based on ribonucleic acid interference, positioning itself in a cutting-edge field of biopharmaceuticals that could lead to significant breakthroughs.

Alnylam Pharmaceuticals Bear Case

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

  • The stock has experienced a decline of 3.2% recently, which may raise concerns about its short-term performance and market volatility.
  • Insider selling has been notable, with executives selling a total of 73,964 shares worth over $20 million in the last three months, which could signal a lack of confidence in the stock's near-term prospects.
  • Alnylam Pharmaceuticals, Inc. has a negative price-to-earnings ratio of -97.88, indicating that the company is not currently profitable, which can be a red flag for potential investors.
  • The company has a relatively high debt-to-equity ratio of 31.64, suggesting that it relies heavily on debt financing, which could pose risks if market conditions change.
  • Despite a strong pipeline, the biopharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact the company's ability to bring new products to market successfully.

Recent News